KRW 23550.0
(3.06%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 7.81 Billion KRW | -85.89% |
2022 | 55.35 Billion KRW | -10.79% |
2021 | 62.05 Billion KRW | 174.07% |
2020 | 22.64 Billion KRW | 361.64% |
2019 | 4.9 Billion KRW | 70.97% |
2018 | 2.86 Billion KRW | 42.44% |
2017 | 2.01 Billion KRW | 2.97% |
2016 | 1.95 Billion KRW | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 7.89 Billion KRW | 4.57% |
2024 Q1 | 7.55 Billion KRW | -3.32% |
2023 Q4 | 7.81 Billion KRW | -13.31% |
2023 Q3 | 9.01 Billion KRW | -58.97% |
2023 Q2 | 21.96 Billion KRW | -60.1% |
2023 Q1 | 55.04 Billion KRW | -0.56% |
2023 FY | 7.81 Billion KRW | -85.89% |
2022 Q4 | 55.35 Billion KRW | -4.67% |
2022 Q2 | 58.34 Billion KRW | -11.24% |
2022 Q1 | 65.73 Billion KRW | 5.94% |
2022 Q3 | 58.06 Billion KRW | -0.49% |
2021 Q4 | 62.05 Billion KRW | -5.43% |
2021 Q3 | 65.61 Billion KRW | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
HLB Co., Ltd. | 169.47 Billion KRW | 95.39% |
iNtRON Biotechnology, Inc. | 1.88 Billion KRW | -315.466% |
BINEX Co., Ltd. | 75.68 Billion KRW | 89.678% |
Bioneer Corporation | 80.61 Billion KRW | 90.309% |
Anterogen.Co.,Ltd. | 19.98 Billion KRW | 60.913% |
MEDIPOST Co., Ltd. | 135.73 Billion KRW | 94.244% |
CrystalGenomics, Inc. | 97.82 Billion USD | 92.014% |
Helixmith Co., Ltd | 73.55 Billion KRW | 89.379% |
Chabiotech Co.,Ltd. | 1069.23 Billion KRW | 99.269% |
Medy-Tox Inc. | 137.14 Billion KRW | 94.303% |
Peptron, Inc. | 16.36 Billion KRW | 52.274% |
Amicogen, Inc. | 248.12 Billion KRW | 96.851% |
Genexine, Inc. | 79.68 Billion KRW | 90.196% |
HLB Therapeutics Co.,Ltd. | 29.27 Billion KRW | 73.315% |
LegoChem Biosciences, Inc. | 41.28 Billion KRW | 81.075% |
ALTEOGEN Inc. | 108.25 Billion KRW | 92.784% |
PharmaResearch Co., Ltd. | 73.08 Billion KRW | 89.311% |
SillaJen, Inc. | 19.4 Billion KRW | 59.733% |
JETEMA, Co., Ltd. | 179.09 Billion KRW | 95.638% |
OliX Pharmaceuticals,Inc | 52.48 Billion KRW | 85.116% |
MedPacto, Inc. | 9.56 Billion KRW | 18.331% |
D&D Pharmatech | 23.98 Billion KRW | 67.429% |
EASY BIO,Inc. | 105.86 Billion KRW | 92.621% |
GI Innovation, Inc. | 9.63 Billion KRW | 18.928% |